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Apparent diffusion coefficient 
histogram in breast cancer brain 
metastases may predict their 
biological subtype and progression
Sung Jun Ahn  1, Mijin Park2, Sungkyu Bang2, Eunseo Cho2, Sung Gwe Ahn3, Sang Hyun Suh1 
& Jong-Min Lee2
Our aims for this study were to investigate the relationship between diffusion weighted image (DWI) 
parameters of brain metastases (BMs) and biological markers of breast cancer, and moreover, to assess 
whether DWI parameters accurately predict patient outcomes. DWI data for 34 patients with BMs 
from breast cancer were retrospectively reviewed. Apparent diffusion coefficient (ADC) histogram 
parameters were calculated from all measurable BMs. Two region of interest (ROI) methods are used 
for the analysis: from the largest BM or from all measurable BMs per one patient. ADC histogram 
parameters were compared between positive and negative groups depending on ER/PR and HER2 
statuses. Overall survival analysis after BM (OSBM) and BM-specific progression-free survival (BMPFS) 
was analyzed with ADC parameters. Regardless of ROI methods, 25th percentile of ADC histogram 
was significantly lower in the ER/PR-positive group than in the ER/PR-negative group (P < 0.05). Using 
ROIs from all measurable BMs, Peak location, 50th percentile, 75th percentile, and mean value of ADC 
histogram were also significantly lower in the ER/PR-positive group than in the ER/PR-negative group 
(P < 0.05). However, there was no significant difference between HER2-postive and negative group. 
On univariate analysis, using ROIs from all measurable BMs, lower 25th percentile, 50th percentile 
and mean of ADC were significant predictors for poor BMPFS. ADC histogram analysis may have a 
prognostic value over ER/PR status as well as BMPFS.
Breast cancer is the most common cancer in women world-wide and constitutes the second-most frequent cause 
of brain metastases (BMs), which occur in 10–16% of patients1–3. The incidence of BMs has increased in recent 
years, which is likely because of the prolonged survival of patients who receive more efficient treatments, along 
with the availability of better imaging techniques that enable increased detection of BM2,4. Despite the advent 
of better systemic therapies, BMs are a major cause of morbidity and are associated with progressive neurologic 
deficits that reduce quality of life5.
Breast cancer can be divided into three biologic subtypes, based on biomarkers such as the estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2). Each subtype exhibits a dis-
tinct prognostic significance6,7. The subgroups of patients with triple-negative and HER2-positive breast cancer 
are at high risk for the development of BMs8,9. The onset of BMs occurs earlier in triple-negative breast cancer 
than in other subtypes, and the overall survival rate in these cases is particularly poor10. In addition, it is crucial 
to consider ER/PR and HER2 statuses, both for prognosis and for understanding the different systemic thera-
pies available; importantly, HER2-targeted therapy successfully improved the overall survival in patients with 
HER2-positive breast cancer11.
Diffusion-weighted magnetic resonance (MR) imaging (DWI) of the brain is based on differential diffusion 
rates or the Brownian motion of water. It is an essential technique for diagnosing acute infarction in the brain 
because of its ability to detect the cytotoxic edema that is caused by altered water diffusion, secondary to cel-
lular damage. DWI is also widely used for the assessment of tumor pathology in the field of neuro-oncology12. 
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Specifically, apparent diffusion coefficient (ADC) values derived from DWI have been shown to correlate with 
tumor cellularity, glioma grade, and treatment response12–16.
We hypothesized that DWI parameters might correlate with biomarkers and patient prognosis in breast cancer 
patients with BMs. Our aims for this study were two-fold: (1) to investigate the relationship between DWI param-
eters and the HER-2 and ER/PR statuses of breast cancer, and (2) to assess whether DWI parameters accurately 
predict patient outcomes.
Materials and Methods
Participants. We retrospectively reviewed data for breast cancer patients with BMs who underwent gado-
linium-enhanced brain MRI from 2011 to 2017. A total of 94 patients were identified. Of these, 58 patients were 
excluded for the following reasons: (1) previous neurosurgery or brain radiation therapy (n = 15); (2) presence 
of other malignant disease (n = 7); (3) absence of the immunohistochemistry profile of breast cancer (n = 15); 
(4) absence of diffusion-weighted images (n = 21); (5) poor image quality (n = 2). A total of 34 patients remained 
after exclusion was completed. Immunohistochemistry was performed to evaluate the levels of ER, PR, and HER2 
expression in primary breast cancer. Fluorescent in situ hybridization analysis of HER2 amplification was per-
formed inimmunohistochemistry 2 + cases. The current study design and use of clinical data was approved by 
Gangnam severance hospital institutional review board (protocol # 3-2017-0175). All experiments were carried 
out in accordance with approved guidelines. The requirement to obtain informed consent was waived, and all 
data were fully anonymized. Overall survival analysis after BM (OSBM) was defined as the time from initial BM 
diagnosis to the time of death or last follow-up. BM-specific progression-free survival (BMPFS) was defined as 
the time from the initial BM diagnosis to the time of BM progression.
Imaging. All patients were imaged with a 3 T clinical MR imaging device (Discovery MR750, GE Healthcare, 
Milwaukee, Wisconsin, USA). Our MR imaging protocol for BM included routine diffusion-weighted 
echo-planar sequences (TR/TE, 8000/65.6 ms; slice thickness/intersection gap, 4/1 mm; matrix size, 160 × 160; 
FOV, 240 × 240 mm; three directions; b-value = 0 and 1000 s/mm2), and T2-weighted fast-spin-echo sequences 
(repetition time/echo time (TR/TE), 5414/96 ms). After intravenous gadolinium-based contrast agent was 
administered at a dose of 0.1 mmol/kg body weight, axial fluid-attenuated inversion recovery sequences (TR/TE/
inversion time (TI), 4000/80/2000 ms) and 3D T1 fast-spoiled gradient-recalled sequences (TR/TE, 8.2/3.2 ms; 
flip angle 12°; slice thickness, 1 mm; matrix size, 256 × 256; FOV, 220 × 220 mm) were taken sequentially. ADC 
values were automatically calculated by the operating console of the MR imaging device and were displayed as 
corresponding ADC maps.
Image postprocessing and analysis. We regarded a BM as measurable when its volume is more than 
100 mm3, because with the volume of less than 100 mm3, it is difficult to draw ROIs exactly and co register to ADC 
space correctly. Regions of interest (ROIs) were drawn on each tumor section on contrast-enhanced T1-weighted 
images using a free open-source toolkit, ITK-SNAP (www.itksnap.org)17. ROI drawings were not performed 
for non-measurable BMs. The ROI masks were automatically segmented with intensity thresholds; incomplete 
regions of the entire enhancing tumor were manually corrected. ROIs were co-registered to ADC maps via affine 
transformation with normalized mutual information as a cost function18. ADC histograms were generated with 
a bin of 1 × 10−5 mm2/sec and a range of 10–3000 × 10−6 mm2/sec. We considered ADC values <10 × 10−6 mm2/
sec to be artifacts and values >3000 × 10−6 mm2/sec to be cystic portions. ADC histogram parameters (peak 
location, 25th and 75th percentile values, median, mean, and standard deviation) were calculated from ROIs that 
were overlaid on ADC maps. A representative case is presented in Fig. 1.
Statistical analysis. Overall, we used two ROI methods for our study: First one is to use a ROI of largest BM 
from one patients. In this case, we used a total of 34 ROIs for analysis. Second one is to use ROIs from all measura-
ble BMs. In this case, we used a total of 85 ROIs for analysis. ADC histogram parameters were compared between 
positive and negative groups depending on ER/PR and HER2 statuses, using a two-sample t-test. ADC variables 
were dichotomized into two groups by median and univariate survival analyses were performed to identify ADC 
variables to stratify OSBM and BMPFS, using a log-rank test.
Results
Patient characteristics. Patient characteristics are summarized in Table 1. No significant differences 
were found in clinical characteristics between groups (HER2-positive vs negative, ER/PR-postive vs negative). 
Mean ages at the initial diagnosis were 46.4 ± 12.8 years vs 46.6 ± 11.1 years (HER2-negative vs HER2-positive, 
p = 0.96), 45.3 ± 9.9 years vs 48.2 ± 14 years (ER/PR-negative vs ENR/PR positive, p = 0.51). The majority of 
tumor histologic type was ductal carcinoma. All BM patients underwent at least one treatment (surgery, radiation 
or systemic therapy). Volumes and diameters of BMs were not significantly different between groups. Mean diam-
eters of largest BM were 19.9 ± 9.1 mm vs 20.3 ± 7.5 mm (HER2-negative vs positive, p = 0.86) and 18.5 ± 7.9 mm 
vs 22.0 ± 8.4 mm (ER/PR negative vs positive, p = 0.21). Mean volumes of largest BM were 6895 ± 10024 mm3 
vs 6044 ± 5123 mm3 (HER2-negative vs positive, p = 0.86) and 5132 ± 6325 mm3 vs 7920 ± 8994 mm3 (ER/PR 
negative vs positive, p = 0.3). The number of measurable BMs were 85. Mean diameters of measurable BMs were 
14.1 ± 7.2 mm vs 15.6 ± 7.4 mm (HER2-negative vs positive, p = 0.34) and 14.3 ± 6.7 mm vs 15.4 ± 7.8 mm (ER/
PR-negative vs positive, p = 0.49). Mean volumes of measurable BMs were 2962 ± 6435 mm3 vs 3423 ± 4352 mm3 
(HER2-negative vs positive, p = 0.69) and 2717 ± 4557 mm3 vs 3629 ± 6463 mm3 (ER/PR negative vs positive, 
p = 0.45). The mean number of measurable BMs per patient were 2.9 ± 2.9 vs 2.1 ± 2.0 (HER2-negative vs posi-
tive, p = 0.33) and 2.4 ± 2.4 vs 2.6 ± 2.6 (ER/PR negative vs positive, p = 0.78).
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Relationship between ADC histogram and biological subtype. Regardless of ROI methods, ADC 
variables were not significantly different between HER2-positive and -negative groups. However, between 
ER/PR positive and negative groups, there was significant differences. Using ROI from largest BMs, 25th per-
centile of ADC histogram was significantly lower in the ER/PR-positive group than in the ER/PR-negative 
group (840 ± 184 × 10−6 mm2 vs. 965 ± 133 × 10−6 mm2/sec, p < 0.05, Table 2). Using ROIs from all measur-
able BMs, Peak location, 25th percentile, 50th percentile, 75th percentile and mean of ADC histogram were 
significantly lower in the ER/PR-positive group than in the ER/PR-negative group (899 ± 228 × 10−6 mm2 vs. 
1020 ± 275 × 10−6 mm2/sec, 822 ± 176 × 10−6 mm2 vs. 943 ± 153 × 10−6 mm2, 951 ± 211 × 10−6 mm2/sec vs. 
1091 ± 223 × 10−6 mm2/sec, 1127 ± 227 × 10−6 mm2 vs. 1282 ± 282 × 10−6 mm2, and 991 ± 215 × 10−6 mm2 
vs. 1136 ± 211 × 10−6 mm2 respectively, p < 0.05, Table 3). Other ADC variables were not significantly different 
between ER/PR-positive and -negative groups.
Prediction of overall survival after brain metastasis and brain metastasis-specific 
progression-free survival. On univariate analysis with ROI of largest BM, ADC variables were not signifi-
cant prognostic factors for OSBM and BMPFS. However, with ROIs from all measurable BMs, peak location, 25th 
percentile, 50th percentile, and mean of ADC histogram were significant prognostic factors for BMPFS but not 
for OSBM, p < 0.05, Table 4). Lower ADC variables showed poor BMPFS (Fig. 2).
Discussion
In this study, we tested the hypothesis that ADC histogram analysis of BMs can accurately predict the biolog-
ical subtypes of breast cancer, and patients’ outcomes. Our results indicated that ER/PR-positive patients have 
significantly lower 25th percentile of ADC values in BM, compared with ER/PR-negative patients, regardless of 
ROI methods (ROIs from largest BMs or ROIs from all measurable BMs). Using ROIs from all measurable BMs, 
peak location, 50th percentile, 75th percentile and mean of ADC were also significantly lower in ER/PR-positive 
patients than in ER/PR negative-patients. However, ADC variables are not correlated with HER2. Using ROIs 
from all measurable BMs, peak location, 25th percentile, 50th percentile, and mean of ADC significantly pre-
dicted BMPFS, thus they could be a potential prognostic biomarker for BMPFS.
Figure 1. Processing workflow diagram. (A) contrast-enhanced T1-weighted MR image, (B) contrast-
enhanced T1-weighted MR image with ROIs to segment the entire enhancing BM, (C) ADC map with the ROI 
of the entire BM overlaid, and (D) ADC histogram extracted from ROIs.
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A few previous studies have demonstrated a relationship between DWI and BMs. Hayashida et al. evaluated 26 
brain metastatic lesions, reporting that small- and large-cell neuroendocrine carcinomas exhibited high signal inten-
sity on DWI. However, their primary lesions generally consisted of lung cancer, and included only one case of primary 
breast cancer16. Duygulu et al. studied 87 patients, but concluded that DWI is not correlated with primary tumor 
histopathology; although their report included 20 breast carcinomas, they did not perform a subgroup analysis19. 
Jung et al. limited their cohort to patients with BMs from primary lung cancer; their results demonstrated that ADC 
values from DWI are significantly correlated with EGFR mutation status, rather than with histology20. However, to 
date, no research has examined the relationship between ADC values and biological features of BMs from primary 
breast cancer. In the current study, all ADC variables in BMs from breast cancer revealed a decreasing trend in the 
ER/PR-positive group, compared with the ER/PR-negative group. This result is consistent with previous results in 
which the median ADC values of primary breast cancer were significantly lower in the ER-positive group than in the 
ER-negative group21,22. This phenomenon can be explained as follows: the ADC value is affected by the molecular 
diffusion of water, as well as by perfusion23,24. Studies using experimental models have shown that ERs inhibit the 
angiogenic pathway and induce a decrease in perfusion, thus affecting the ADC value25. Another noticeable thing 
HER2-negative 
(n = 16)
HER2-positive 
(n = 18) P-value
ER/PR-negative 
(n = 18)
ER/PR-positive 
(n = 16) P-value
Age at initial diagnosis, years 46.4 ± 12.8 46.6 ± 11.1 0.96 45.3 ± 9.9 48.2 ± 14.0 0.5
Initial TNM stage 0.66 0.09
I 1 (6.2%) 3 (16.7%) 3 (16.7%) 1 (6.2%)
II 8 (50.0%) 6 (33.3%) 5 (27.8%) 9 (56.2%)
III 4 (25.0%) 6 (33.3%) 8 (44.4%) 2 (12.5%)
IV 3 (18.8%) 3 (16.7%) 2 (11.1%) 4 (25.0%)
Histology 0.17 0.15
Ductal carcinoma 15 (93.8%) 14 (77.8%) 16 (88.9%) 13 (81.2%)
Lobular carcinoma 0 (0.0%) 1 (5.6%) 1 (5.6%) 0 (0.0%)
Metaplastic carcinoma 1 (6.2%) 0 (0.0%) 1 (5.6%) 0 (0.0%)
Unknown 0 (0.0%) 3 (16.7%) 0 (0.0%) 3 (18.8%)
Systemic therapy after BM 0.13 0.77
Yes 11 (68.8%) 17 (94.4%) 14 (77.8%) 14 (87.5%)
No 5 (31.2%) 1 (5.6%) 4 (22.2%) 2 (12.5%)
Surgery after BM 0.73 0.73
Yes 7 (43.8%) 10 (55.6%) 8 (44.4%) 9 (56.2%)
No 9 (56.2%) 8 (44.4%) 10 (55.6%) 7 (43.8%)
Radiation therapy after BM 0.17 0.87
Yes 9 (56.2%) 15 (83.3%) 12 (66.7%) 12 (75.0%)
No 7 (43.8%) 3 (16.7%) 6 (33.3%) 4 (25.0%)
Largest BMs
Diameter (mm) 19.9 ± 9.1 20.3 ± 7.5 0.86 18.5 ± 7.9 22.0 ± 8.4 0.21
Volume (mm3) 6895 ± 10024 6044 ± 5123 0.76 5132 ± 6325 7920 ± 8994 0.3
Measurable BMs
Diameter (mm) 14.1 ± 7.2 15.6 ± 7.4 0.34 14.3 ± 6.7 15.4 ± 7.8 0.49
Volume (mm3) 2962 ± 6435 3423 ± 4352 0.69 2717 ± 4577 3629 ± 6463 0.45
Number of BMs per one patient 2.9 ± 2.9 2.1 ± 2.0 0.33 2.4 ± 2.4 2.6 ± 2.6 0.78
Table 1. Characteristics of breast cancer patients with brain metastases. BM, brain metastasis; ER/PR, estrogen 
receptor/progesterone receptor; HER2, human epidermal growth receptor 2; TNM, tumor-nodes.
HER2 status ER/PR status
HER2-negative 
(n = 16)
HER2- positive 
(n = 18) P-value
ER/PR-negative 
(n = 18)
ER/PR- positive 
(n = 16) P-value
Peak location (×10−6 mm2) 1017 ± 279 945 ± 268 0.45 1026 ± 262 926 ± 281 0.29
25th percentile (×10−6 mm2) 933 ± 188 883 ± 152 0.39 965 ± 133 840 ± 184 0.03
50th percentile (×10−6 mm2) 1119 ± 259 1031 ± 215 0.29 1130 ± 229 1007 ± 237 0.13
75th percentile (×10−6 mm2) 1360 ± 320 1248 ± 295 0.29 1351 ± 316 1244 ± 297 0.31
Mean ADC (×10−6 mm2) 1167 ± 239 1088 ± 213 0.31 1179 ± 221 1064 ± 222 0.14
Standard deviation (×10−6 mm2) 327 ± 124 279 ± 113 0.54 291 ± 120 313 ± 120 0.59
Table 2. Comparison of apparent diffusion coefficient (ADC) variables from volume of interest (VOI) of largest 
brain metastasis according to human epidermal growth receptor 2 (HER2) and estrogen receptor/progesterone 
receptor (ER/PR) status.
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in our results is that 25th percentile of ADC shows a significant difference between ER/PR- positive and negative 
groups regardless of ROI methods. There is a dilemma in choosing ROI method: Using a single representative BM 
or all measurable BMs from one patient. Either way has flaws, in case of first method, it is hard to select the rep-
resentative lesion. For the second method, an oversampling issue is raised. However, 25th percentile of ADC is not 
dependent on ROI method and might be useful to differentiate two groups.
Our results showed that ADC variables are not correlated with the HER2 status of BMs from primary breast 
cancer. There has been a controversy regarding this issue in primary breast cancer. Jeh et al. showed that ADC 
variables of primary breast cancer were significantly lower in the HER2-positive group, compared with the 
HER2-negative group26. In contrast, Kim et al. demonstrated that ADC values are not correlated with HER2 status21. 
Notably, HER2 overexpression induces angiogenesis, thus increasing ADC values; however, this overexpression 
also stimulates cell proliferation, thereby decreasing ADC values. Thus, we presume that these contradictory 
effects of HER2 overexpression on ADC values may result in a non-significant relationship between HER2 status 
and ADC values of BMs in breast cancer.
HER2 status ER/PR status
HER2-negative 
(n = 47)
HER2-positive 
(n = 38) P-value
ER/PR-negative 
(n = 43)
ER/PR-positive 
(n = 42) P-value
Peak location(×10−6 mm2) 974 ± 247 943 ± 274 0.58 1020 ± 275 899 ± 228 0.03
25th percentile (×10−6 mm2) 890 ± 193 874 ± 150 0.66 943 ± 153 822 ± 176 <0.01
50th percentile (×10−6 mm2) 1029 ± 242 1012 ± 210 0.73 1091 ± 223 951 ± 211 <0.01
75th percentile (×10−6 mm2) 1209 ± 308 1201 ± 267 0.91 1282 ± 282 1127 ± 277 0.01
Mean ADC (×10−6 mm2) 1068 ± 245 1060 ± 198 0.87 1136 ± 211 991 ± 215 <0.01
Standard deviation (×10−6 mm2) 252 ± 129 256 ± 105 0.87 265.1 ± 108.6 242.7 ± 128.2 0.38
Table 3. Comparison of apparent diffusion coefficient (ADC) variables from volume of interests (VOI) of 
multiple brain metastases according to human epidermal growth receptor 2 (HER2) and estrogen receptor/
progesterone receptor (ER/PR) status.
Variables from 
ADC histogram
ROIs with largest BMs
ROIs with all measurable 
BMs
p-value for 
OSBM
p-value for 
BMPFS
p-value for 
OSBM
p-value for 
BMPFS
Peak location 0.58 0.71 0.41 0.08
25th percentile 0.73 0.31 0.66 0.02
50th percentile 0.38 0.21 0.41 <0.01
75th percentile 0.06 0.44 0.26 0.06
Mean ADC 0.41 0.18 0.48 0.03
Standard deviation 0.22 0.16 0.13 0.24
Table 4. Survivals in breast cancers with brain metastases depending on apparent diffusion coefficient (ADC) 
histogram analysis. BMPFS, Brain metastasis-specific progression-free survival; OSBM, overall survival analysis 
after brain metastasis.
Figure 2. Kaplan-Meier curves for BMPFS show (A) 25th percentile ADC (B) 50th percentile ADC (C) mean 
ADC. 25th percentile, 50% percentile and mean of ADC significantly stratified BMPFS in breast cancer patients, 
using ROI method from all measurable BMs.
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Some studies have postulated a prognostic value for ADC values in primary breast cancer. Nakajo et al. exam-
ined 44 breast cancers, and concluded that a low ADC value is significantly correlated with poor prognosis27. 
Mori et al. investigated 86 patients with luminal type breast cancer and showed that ADC values are correlated 
with the Ki-67 labeling index, which is a significant prognostic factor28. For BMs, Lee et al. evaluated the effect of 
stereotactic radiosurgery on BMs with ADC maps; they found that increased ADC values are indicators of good 
tumor control. However, because their primary tumor origins were heterogenous, it is difficult to apply their 
results to BMs that originate from primary breast cancer. In our study, 25th percentile, 50th percentile, and mean 
of ADC show potentials to predict BMPFS, specifically using ROIs from all measurable BMs.
Our study has a limitation, the number of our cohort is small for multivariate analysis. We could not verified 
our independent predictability of our ADC variables. However, our cohort is rather homogenous because patients 
had been recruited in same institution for a long period (7 years). Also, clinical characteristics between two 
groups (HER2 positive vs negative, ER/PR positive vs negative) are not different. Thus, our results may serve as a 
cornerstone for future studies with a larger population to validate and extend these results.
In conclusion, we demonstrated that ADC variables of BMs in breast cancer are significantly lower in ER/
PR-positive patients than in ER/PR-negative patients. Specifically, the 25th percentile ADC value are consistently 
different between two groups regardless of ROI methods. Also, ADC variables of BMs may be a prognostic indi-
cator for BMPFS of breast cancer but these are necessary to be verified in future study with large cohort.
Data availability. All data generated or analyzed during this study are included in this published article and 
its Supplementary Information files.
References
 1. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62, 220–241 (2012).
 2. Xue, J., Peng, G., Yang, J. S., Ding, Q. & Cheng, J. Predictive factors of brain metastasis in patients with breast cancer. Med Oncol 30, 
337 (2013).
 3. Hofer, S. & Pestalozzi, B. C. Treatment of breast cancer brain metastases. Eur J Pharmacol 717, 84–87 (2013).
 4. Cheng, X. & Hung, M. C. Breast cancer brain metastases. Cancer Metastasis Rev 26, 635–643 (2007).
 5. Klos, K. J. & O’Neill, B. P. Brain metastases. Neurologist 10, 31–46 (2004).
 6. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, 
prognostication and prediction: a retrospective of the last decade. J Pathol 220, 263–280 (2010).
 7. Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and 
long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med 7, e1000279 (2010).
 8. Gabos, Z. et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis 
after newly diagnosed breast cancer. J Clin Oncol 24, 5658–5663 (2006).
 9. Tham, Y. L., Sexton, K., Kramer, R., Hilsenbeck, S. & Elledge, R. Primary breast cancer phenotypes associated with propensity for 
central nervous system metastases. Cancer 107, 696–704 (2006).
 10. Dawood, S. et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20, 621–627 
(2009).
 11. Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372, 724–734 
(2015).
 12. Wieduwilt, M. J. et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic 
assessment by diffusion-weighted MRI. Clin Cancer Res 18, 1146–1155 (2012).
 13. Lee, E. J. et al. Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent 
diffusion coefficient. AJNR Am J Neuroradiol 29, 1872–1877 (2008).
 14. Guo, A. C., Cummings, T. J., Dash, R. C. & Provenzale, J. M. Lymphomas and high-grade astrocytomas: comparison of water 
diffusibility and histologic characteristics. Radiology 224, 177–183 (2002).
 15. Lee, K. C. et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 13, 
443–450 (2007).
 16. Hayashida, Y. et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. 
AJNR Am J Neuroradiol 27, 1419–1425 (2006).
 17. Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and 
reliability. Neuroimage 31, 1116–1128 (2006).
 18. Maes, F., Collignon, A., Vandermeulen, D., Marchal, G. & Suetens, P. Multimodality image registration by maximization of mutual 
information. IEEE Trans Med Imaging 16, 187–198 (1997).
 19. Duygulu, G. et al. Intracerebral metastasis showing restricted diffusion: correlation with histopathologic findings. Eur J Radiol 74, 
117–120 (2010).
 20. Jung, W. S., Park, C. H., Hong, C. K., Suh, S. H. & Ahn, S. J. Diffusion-Weighted Imaging of Brain Metastasis from Lung Cancer: 
Correlation of MRI Parameters with the Histologic Type and Gene Mutation Status. AJNR Am J Neuroradiol https://doi.org/10.3174/
ajnr.A5516. (2018).
 21. Kim, S. H. et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic 
factors. J Magn Reson Imaging 30, 615–620 (2009).
 22. Martincich, L. et al. Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol 22, 1519–1528 
(2012).
 23. Koh, D. M., Collins, D. J. & Orton, M. R. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR 
Am J Roentgenol 196, 1351–1361 (2011).
 24. Le Bihan, D. et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. 
Radiology 161, 401–407 (1986).
 25. Ludovini, V. et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II 
breast cancer patients. Breast Cancer Res Treat 81, 159–168 (2003).
 26. Jeh, S. K. et al. Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with 
prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 33, 102–109 (2011).
 27. Nakajo, M. et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized 
uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 37, 2011–2020 (2010).
 28. Mori, N. et al. Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index. Radiology 
274, 66–73 (2015).
www.nature.com/scientificreports/
7SCiEntifiC REPORts | (2018) 8:9947 | DOI:10.1038/s41598-018-28315-y
Acknowledgements
This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea 
government (MSIP)(No. 2017R1C1B5014927) to S.J.A. This work was supported by the National Research 
Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (2016R1A2B3016609) to J.M.L.
Author Contributions
J.M.L. and S.J.A. designed the study. M.J.P., E.S.C. and S.K.B. performed an image analysis. S.G.A. collected 
patients data. S.H.S. performed a statistical analysis. S.J.A. wrote the manuscript. All authors reviewed the final 
manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28315-y.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
